Adrenomedullin Therapy for Moderate-to-Severe COVID-19 Pneumonia: Double-Blind Placebo-Controlled Phase 2a Trial

Adrenomedullin Therapy for Moderate-to-Severe COVID-19 Pneumonia: Double-Blind Placebo-Controlled Phase 2a Trial

Adrenomedullin (AM) is a bioactive peptide that is strongly induced during severe inflammation, including pneumonia and sepsis, and serves as an organ-protective factor. The plasma concentration of AM is markedly increased in the novel coronavirus disease COVID-19 and is closely related to the sever...

Full description

Saved in:
Bibliographic Details
Main Authors: Toshihiro Kita, Norio Ohmagari, Sho Saito, Hiroshi Mukae, Takahiro Takazono, Taka-Aki Nakada, Tadanaga Shimada, Yuji Hirai, Yuichiro Shindo, Kosaku Komiya, Atsushi Saito, Masaya Yamato, Koichiro Homma, Masaki Okamoto, Yoshihiro Yamamoto, Yoshikazu Mutoh, Chihiro Hasegawa, Nobuaki Mori, Fukumi Nakamura-Uchiyama, Mitsuru Honda, Keisuke Tomii, Hiroshi Ishii, Ichiro Takajo, Koji Watanabe, Kazuo Kitamura
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Viruses
Subjects:
adrenomedullin
COVID-19
pneumonia
mechanical ventilation
phase 2a clinical trial
Japanese
Online Access:https://www.mdpi.com/1999-4915/17/7/982
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1999-4915/17/7/982

Similar Items